UNSPSC 51333403: Blonanserin

This classification denotes a serotonin antagonist with the molecular formula C23H30FN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, AQ316B4F8C chemically known as 2-(4-ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine but generally known as blonanserin, which bears US NIH Compound Identifier 125564. European Medicines Agency schedules Blonanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05864MIG.

UNSPSC 51333403 Blonanserin is a Commodity code for a specific atypical antipsychotic medication, yet the recent state and local opportunities tagged under it reflect a broader pharmaceutical procurement pattern — state and local agencies are buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing vehicles, and exploring direct-to-manufacturer prescription programs to manage pharmacy benefit costs and improve fulfillment efficiency. The actual solicitations under this code show state and local governments purchasing pharmaceutical products and related public health commodities through competitive bidding, RFPs, and requests for information designed to streamline supply chains and reduce intermediary costs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP, administered by the Minnesota Department of Administration). The code reflects procurement activity across general purpose local government, state health agencies, and cooperative purchasing vehicles that serve multiple state and local jurisdictions.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with bids due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs as a preliminary market intelligence phase before formal procurement. MMCAP, administered by Minnesota's Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract awards effective July 1, 2026. All three opportunities require vendors to demonstrate compliance with federal drug-supply regulations, maintain specified insurance coverages, and submit detailed product specifications and pricing models; the MMCAP RFP imposes a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation.